Drug units and step-therapy denials cost rheumatology practices recoverable revenue every day.
Rheumatology runs on high-cost biologic infusions, the initial, sequential, and additional-hour administration hierarchy, and step-therapy documentation, where a single J-code, wastage modifier, or missing auth wipes out a high-dollar claim. Manual billing teams catch a fraction of the errors. Ember catches all of them.
Trusted by specialty groups and health systems
Where rheumatology revenue leaks
The denial patterns Ember was built for
Rheumatology runs high-cost biologic drugs, complex infusion administration, and step-therapy scrutiny side by side, and each line has its own denial trap. Drug units, infusion sequencing, and auth gaps compound into systematic underpayment. Ember closes each gap.
01 · Biologic drug units & wastage
J-code, unit, and wastage errors on high-cost infliximab and rituximab.
Infliximab, rituximab, and other biologics carry high per-dose cost, and the smallest J-code, unit, or wastage-modifier error becomes a denial or takeback on an expensive claim. Buy-and-bill margins disappear when JW and JZ modifiers don't match the documented dose. Ember validates units and documented wastage before the drug is billed.
J1745 · J9312 · J3357 · JW · JZ02 · Infusion administration hierarchy
Initial, sequential, and additional-hour codes miscoded against documented times.
Infusion administration follows a strict initial, sequential, and additional-hour hierarchy tied to documented start and stop times. When those codes are missed or transposed, a full infusion collapses into a partial payment. Ember maps the documented times to the correct administration codes before submission.
96413 · 96415 · 96361 · 9641703 · Prior auth & step therapy
Auth and documentation denials on biologics requiring failed DMARDs.
Payers require documented step therapy and failed conventional DMARDs before approving biologics, and auth obtained doesn't always match the payer's current policy. Documentation gaps trigger denials on high-value drug claims. Ember flags the missing criteria before the service and builds the appeal package when denials occur.
J1745 · J1602 · 96413 · L38246Three engines.
One source of truth.
Ember connects clinical documentation, payer policy, and contract terms into a single intelligence layer. Built for the buy-and-bill, infusion-hierarchy, and step-therapy mix rheumatology billing spans every day.
01 · Foundation
Data Engine
Bridges the clinical and the financial. Unifies documentation, coding decisions, payer policy, and contracts across every encounter and provider.
M. Delgado
Encounter #R-61207
02 · Audit
Coding Engine
Reviews 100% of encounters against national standards, payer-specific policies, your internal guidelines, and your payer contracts. Every flag carries a rule citation.
Append modifier JZ — zero drug wastage
CMS JW/JZ policy · confidence 0.96
03 · Recovery
Appeal Engine
Reads CARC and RARC codes, identifies the applicable LCD/NCD policy and contract terms, drafts the appeal letter, packages documentation, and tracks every claim to adjudication.
Re: Claim #R-61207 · Denial CO-50
Infliximab meets medical-necessity criteria under LCD L38246: documented active rheumatoid arthritis and failed conventional DMARDs, per contract §4.7…
Audit upstream.
Appeal downstream.
Two workflows do most of the work for rheumatology practices. The first prevents denials before they happen. The second recovers the ones that slip through.
Pre-bill audit
Catch the drug-unit and infusion issue before the claim leaves.
Ember reviews every encounter against coding standards, payer drug and infusion policy, and your contracts. Drug-unit and wastage gaps, infusion-sequencing errors, and step-therapy issues are flagged before submission.
- 1
Ingest the encounter
Pulls infusion records, drug administration logs, procedure codes, and start/stop times from your EHR and practice management system.
- 2
Validate against rules
Checks biologic drug units and wastage, the initial/sequential/additional-hour infusion hierarchy, step-therapy and prior-auth status, and medical-necessity criteria against each payer's specific policies.
- 3
Recommend with citation
Returns the suggested correction tied to the exact payer policy, JW/JZ rule, or contract term.
- 4
Educate the provider
Coding patterns drive provider-level coaching, so infusion documentation and drug charge capture improve across every clinician.
Add JZ + 96415 — zero wastage, additional infusion hour
CMS JW/JZ policy · confidence 0.97
+23%
Clean-claim rate
100%
Encounters reviewed
+5%
Net collection rate
Automated appeals
Pull. Review. Push.
When a denial occurs, Ember identifies the root cause, retrieves infusion records, drug administration logs, and step-therapy documentation, references payer policy and contract terms, drafts the appeal, and tracks it through adjudication.
Medical necessity
Units / wastage
Infusion bundling
Drug auth / step therapy not on file
Biologic appeal
-57%
Denial rate
-45%
Cost to collect
+9.3%
Net revenue per appt
The full revenue cycle
From eligibility to adjudication. Covered.
Audit and appeals are the workhorses, but Ember protects rheumatology revenue at every stage of the cycle.
Eligibility Verification
Confirms active coverage and drug and infusion benefit structure before the visit, and flags buy-and-bill coverage gaps before they become billing problems.
Prior Authorization
Checks auth requirements in real time for biologics and confirms documented step therapy and failed conventional DMARDs, generates medical-necessity documentation, and submits to payer portals automatically.
AI Medical Coding
Reviews 100% of encounters, biologic drug units and wastage and the initial/sequential/additional-hour infusion hierarchy, against national standards and payer rules before claims submit.
Pre-bill Audit
Predicts and prevents denials before claims go out, catching drug-unit and wastage gaps, infusion-sequencing errors, and step-therapy issues before they generate write-offs.
Denial Management
Full appeal lifecycle for every rheumatology denial type, step-therapy dispute, medical necessity, drug auth failure, and units/wastage error, tracked to adjudication.
Underpayment Recovery
Parses contracts to model what each biologic and infusion claim should pay, then surfaces line-item underpayments on high-cost drug claims at scale.
High-dollar biologic revenue, recovered
-57%
denial rate
-45%
cost to collect
100%
encounters audited
3 days
to first results
Based on Ember AI benchmarks across customer practices. Results vary by payer mix and specialty.
Frequently asked questions
Everything you need to know about how Ember fits into your revenue cycle.
- 50-75% reduction in FTE hours
- Faster cash acceleration
- Prevent 55%+ of denials
We provide ROI benchmarks and dashboards so you can track outcomes from day one.
See what your rheumatology practice is leaving on the table
Bring us 30 days of denial data. We'll show you where the revenue is and exactly how Ember would recover it.